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Abstract
Background: Overuse of broad-spectrum antibiotics is associated with antibiotic resistance.
Acute otitis media (AOM) is responsible for a large proportion of antibiotics prescribed for US
children. Rates of broad-spectrum antibiotic prescribing for AOM are unknown.
Methods:  Analysis of the National Ambulatory Medical Care Survey and National Hospital
Ambulatory Medical Care Survey, 1998 to 2004 (N = 6,878). Setting is office-based physicians,
hospital outpatient departments, and emergency departments. Patients are children aged 12 years
and younger prescribed antibiotics for acute otitis media. Main outcome measure is percentage of
broad-spectrum antibiotics, defined as amoxicillin/clavulanate, macrolides, cephalosporins and
quinolones.
Results: Broad-spectrum prescribing for acute otitis media increased from 34% of visits in 1998
to 45% of visits in 2004 (P < .001 for trend). The trend was primarily attributable to an increase in
prescribing of amoxicillin/clavulanate (8% to 15%; P < .001 for trend) and macrolides (9% to 15%;
P < .001 for trend). Prescribing remained stable for amoxicillin and cephalosporins while decreasing
for narrow-spectrum agents (12% to 3%; P < .001 for trend) over the study period. Independent
predictors of broad-spectrum antibiotic prescribing were ear pain, non-white race, public and
other insurance (compared to private), hospital outpatient department setting, emergency
department setting, and West region (compared to South and Midwest regions), each of which was
associated with lower rates of broad-spectrum prescribing. Age and fever were not associated with
prescribing choice.
Conclusion:  Prescribing of broad-spectrum antibiotics for acute otitis media has steadily
increased from 1998 to 2004. Associations with non-clinical factors suggest potential for
improvement in prescribing practice.
Background
Use and overuse of antibiotics is associated with the devel-
opment and spread of resistant bacteria [1]; a problem
continuing to gain attention from national organizations
as a significant threat to the public health [2]. It is impor-
tant to avoid unnecessary pediatric antibiotic use because
children represent a large reservoir for resistant organisms
[3]. Acute otitis media (AOM) accounts for up to 40% to
50% of antibiotics prescribed for United States children
less than 2 years of age [4]. Encouragingly, overall pediat-
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ric antibiotic prescribing has declined recently [5,6], and
visits for AOM have decreased, apparently in conjunction
with implementation of the pneumococcal conjugate vac-
cine (PCV)[4,7], although PCV only has a marginal effect
on decreasing AOM episodes for an individual child [8].
Visit-rate prescribing of antibiotics for AOM, however, has
not decreased [6].
Antibiotic treatment is recommended for most children
with AOM in the United States [9,10] with therapy tar-
geted primarily at Streptococcus pneumoniae, the most
frequent, clinical pathogen [11,12]. Amoxicillin remains
the recommended first-line therapy for uncomplicated
cases [9,11], but as resistant strains of Streptococcus pneu-
moniae have increased considerably in the past 20 years
[13-15] there is concern of increased prescribing of broad-
spectrum agents. A counteracting factor to this concern is
the effectiveness of PCV in reducing resistant strains of
Streptococcus pneumoniae [16,17]. By providing reassur-
ance that common pathogens are still sensitive to amoxi-
cillin, PCV may mitigate antibiotic choices for broader
coverage. It is important for the Centers for Disease Con-
trol and Prevention (CDC) and other national organiza-
tions involved in curtailing antibiotic resistance to gain a
better understanding on how physicians have responded
to these influences in their prescribing choices for AOM.
To measure changes in the rate of broad-spectrum and
other types of antibiotics prescribed to children seen with
a diagnosis of AOM, data was analyzed from the National
Ambulatory Medical Care Survey (NAMCS) and National
Hospital Ambulatory Medical Care Survey (NHAMCS)
from 1998 to 2004. The NAMCS and NHAMCS are the
only surveys of outpatient settings in the United States
that collect prescribing information and produce unbi-
ased national estimates. These data allow for a compre-
hensive assessment of the antibiotic prescribing for
children with AOM on a national level over time.
Methods
Study Design and Administration
Data for this study was compiled from the 1998 – 2004
NAMCS and NHAMCS. The surveys are administered by
the National Center for Health Statistics (NCHS) for the
CDC. The NAMCS collects information on patient visits
to non-federally funded, community, office-based physi-
cian practices in the United States. Federally qualified
health centers and non-federal government clinics are
included in the database. NAMCS has a three-tiered
design based on geographic location, physician specialty
and individual visits within the practice. The NCHS
weighs each visit by taking into account practice location
and physician specialty. Physicians are randomly selected
from the master files of the American Medical Association
and the American Osteopathic Association. Each physi-
cian is randomly assigned to a one-week reporting period.
During this period, data for a systematic random sample
of visits is recorded by the physician or office staff on a
standardized encounter form provided for that purpose
and checked for completeness by NCHS field staff. Physi-
cians in the sample complete 30 records over a one week
period.
The NHAMCS measures utilization and provision of
ambulatory care services at US hospitals. Using a 4-stage
probability sample design, NHAMCS collects a nationally
representative sample of visits to hospital outpatient
departments and emergency departments based in non-
federal general and short-stay hospitals. NHAMCS data is
collected by hospital staff members at sampled hospitals
and monitored by NHAMCS field representatives. Visit
information is collected during a randomly assigned 4-
week reporting period each year. The NCHS institutional
review board approved the protocols for the NAMCS and
NHAMCS, including a waiver of the requirement for
informed consent. Further description of the NAMCS and
NHAMCS methodology is available from the NCHS
[18,19].
Study Sample: Episodes of Care for Acute Otitis Media
Up to 3 diagnoses were recorded for each visit as free text
and then coded using the International Classification of
Diseases, Ninth Revision (ICD-9)[20]. Visits with the fol-
lowing diagnoses (ICD-9-CM diagnosis of 381.0 – acute
nonsuppurative otitis media, 381.4 – nonsuppurative oti-
tis media, not specified as acute or chronic, 382.0 – acute
suppurative otitis media, 382.4 – unspecified suppurative
otitis media, or 382.9 – unspecified otitis media) were
included. Visits with an alternative diagnosis that could
have justified an antibiotic prescription were excluded.
These were visits with diagnoses such as acute sinusitis
(ICD-9-CM 461), chronic sinusitis (ICD-9-CM 473),
acute pharyngitis (ICD-9-CM 462), acute tonsillitis (ICD-
9-CM 463), streptococcal sore throat (ICD-9-CM 034.0),
or pneumonia (ICD-9-CM 481 – 486). Additionally, visits
were recorded as being for an acute or chronic problem.
To focus specifically on acute episodes of otitis media, vis-
its coded as a chronic problem were excluded from the
study sample.
Covariates
Patient age up to 12 years old (collapsed to < 2 years, ≥ 2
years), sex, race (categories collapsed to white or non-
white), and insurance status (categories collapsed to pri-
vate, Medicare/Medicaid, or other) were recorded for each
visit. Provider self-selected specialty (NAMCS) and clinic
type (NHAMCS) were coded as pediatrics (includes pedi-
atric clinic), family practice (includes general medical
clinic) or otolaryngology (includes surgery clinic). Geo-
graphic region was recorded as well. Up to 3 "complaints,BMC Pediatrics 2009, 9:41 http://www.biomedcentral.com/1471-2431/9/41
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symptoms, or other reason(s) for visit" were abstracted as
free text and then coded centrally using a standard reason
for visit classification (RVC) system [18,19]. Visits with
symptoms of ear pain (RCV code 13551) and fever (RCV
code 10100) were identified.
Outcome: Antibiotics Prescribed
Up to 6 medications (8 since 2003) were recorded for
each visit. Medications were coded via an ambulatory care
drug database coding system [21]. Antibiotics were iden-
tified by using the National Drug Code Directory class
prefix 03 ("antimicrobials") and excluded polymyxins,
aminoglycosides, antimycobacterial, antifungal, and anti-
viral agents. Topical agents including topical anti-infec-
tives (drug class code 1271) and topical otics (drug class
code 1670) were excluded. Amoxicillin was defined to
include ampicillin. Narrow-spectrum agents other than
amoxicillin were primarily trimethoprim/sulfamethoxa-
zole or erythromycin compounds. Broad-spectrum agents
were defined to include amoxicillin/clavulanate, cepha-
losporins, macrolides (except erythromycin), and qui-
nolones. Visits with a quinolone prescription comprised
only 1% of sample records and thus were not sufficient for
a separate trend analysis. If more than 1 antibiotic was
used in a single visit (4% of sample records), we counted
each antibiotic prescribed in its respective subclass, but
the visit only counted once as an episode of care in which
an antibiotic was prescribed for the trend analyses. If a
patient received both a broad-spectrum and a narrow-
spectrum antibiotic, we considered the visit as one in
which a broad-spectrum antibiotic was prescribed for that
trend analysis.
Data Analysis
Categorical variables were evaluated with the χ2 test. Lin-
ear regression, with calendar year as a predictor variable,
was used to analyze time trends. In order to control for
potential confounding variables a multivariate logistic
regression model was developed to determine associa-
tions with receipt of a broad-spectrum antibiotic prescrip-
tion, while controlling for age, race, calendar year,
insurance status, geographical region, visit setting, physi-
cian specialty, and symptoms of ear pain or fever. Popula-
tion estimates were based on the survey weights that
accounted for the complex survey design by using the svy
command provided in Stata version 10 (StataCorp, Col-
lege Station, Texas). All P values are 2-tailed; P < .05 was
considered significant.
Repeat visits by the same individual are not accounted for
because unique identifiers are not provided in the surveys.
However, because data are drawn from 1 weeks' duration
at a given office (NAMCS) or 4 weeks' duration at a given
facility (NHAMCS), repeated visits are likely to be rela-
tively uncommon in the accrued data.
Results
Antibiotic Prescribing Trends
The 1998 – 2004 NAMCS and NHAMCS were conducted
on encounters from 693,505 patient visit records. After
excluding visits with a concomitant non-AOM, antibiotic-
appropriate, diagnosis, 8325 records remained. Over the
7-year study period physicians prescribed antibiotics in
83% (6878/8325) of AOM visits. Broad-spectrum antibi-
otics were prescribed in 41% (2839/6878) and amoxicil-
lin was prescribed in 56% (3880/6878) of visits in which
an antibiotic was prescribed (Table 1). Broad-spectrum
antibiotic prescribing increased from 34% of visits in
1998 to 45% of visits in 2004 (P < .001 for trend) (Figures
1, 2, 3, 4, 5 and 6). The broad-spectrum trend was attrib-
utable to an increase in the prescribing of amoxicillin/cla-
vulanate (8% to 15%; P < .001 for trend), macrolides (9%
to 15%; P < .001 for trend) (Figures 1, 2, 3, 4, 5 and 6).
Cephalosporin (18% to 15%; P = .46 for trend) and
amoxicillin prescribing (54% to 53%; P = .96 for trend)
remained stable (Figures 1, 2, 3, 4, 5 and 6). Prescribing of
narrow-spectrum agents other than amoxicillin decreased
(12% to 3%; P < .001 for trend) over the study period (Fig-
ure 1, 2, 3, 4, 5 and 6).
In multivariable logistic regression modeling, the only
independent positive predictor of broad-spectrum antibi-
otic prescribing was calendar year (odds ratio [OR], 1.07
per year; 95% CI, 1.05–1.10) (Table 2). The other inde-
pendent predictors of broad-spectrum antibiotic prescrib-
ing; ear pain, non-white race, Medicare/Medicaid or other
Table 1: Types of antibiotics prescribed for children with acute 
otitis media in United States physician's offices, hospital 
outpatient departments and emergency departments 1998 to 
2004 (N = 6878)
Antibiotic Number of Visits % of Visits
Narrow-spectrum agents
Amoxicillin 3880* 56
Other narrow-spectrum agents 448† 7
Total 4328 63
Broad-spectrum agents
Cephalosporins 1076 16
Amoxicillin/clavulanate 848 12
Macrolides 841 12
Quinolones 74 1
Total 2839‡ 41
All antibiotics 7167 104§
Abbreviations: CI, confidence interval.
*Includes 129 visits in which both amoxicillin and a broad-spectrum 
agent were prescribed.
†Includes 26 visits in which both another narrow-spectrum agent and 
a broad-spectrum and were prescribed.
‡Two broad-spectrum agents were prescribed in 120 visits.
§More than one antibiotic was prescribed in 4% (285/6878) of visits.BMC Pediatrics 2009, 9:41 http://www.biomedcentral.com/1471-2431/9/41
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Trends in antibiotic prescribing for children with acute otitis media in the United States, 1998–2004 Figure 1
Trends in antibiotic prescribing for children with acute otitis media in the United States, 1998–2004. Based on 
6878 visits in the National Ambulatory Medical Care Survey and National Hospital Ambulatory Care Survey.
Amoxicillin 

Trends in Macrolides prescribing for children with acute otitis media in the United States, 1998–2004 Figure 2
Trends in Macrolides prescribing for children with acute otitis media in the United States, 1998–2004. Based on 
6878 visits in the National Ambulatory Medical Care Survey and National Hospital Ambulatory Care Survey.
Macrolides 
BMC Pediatrics 2009, 9:41 http://www.biomedcentral.com/1471-2431/9/41
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Trends in Narrow-Spectrum Agents, other than Amoxicillin prescribing for children with acute otitis media in the United  States, 1998–2004 Figure 3
Trends in Narrow-Spectrum Agents, other than Amoxicillin prescribing for children with acute otitis media in 
the United States, 1998–2004. Based on 6878 visits in the National Ambulatory Medical Care Survey and National Hospital 
Ambulatory Care Survey.
Narrow-Spectrum Agents, other than Amoxicillin 

Trends in Cephalosporins, other than Amoxicillin prescribing for children with acute otitis media in the United States, 1998– 2004 Figure 4
Trends in Cephalosporins, other than Amoxicillin prescribing for children with acute otitis media in the 
United States, 1998–2004. Based on 6878 visits in the National Ambulatory Medical Care Survey and National Hospital 
Ambulatory Care Survey.
Cephalosporins 
BMC Pediatrics 2009, 9:41 http://www.biomedcentral.com/1471-2431/9/41
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Trends in Amoxicillin/Clavulanate prescribing for children with acute otitis media in the United States, 1998–2004 Figure 5
Trends in Amoxicillin/Clavulanate prescribing for children with acute otitis media in the United States, 1998–
2004. Based on 6878 visits in the National Ambulatory Medical Care Survey and National Hospital Ambulatory Care Survey.
Amoxicillin/Clavulanate 

Trends in Broad-Spectrum Agents prescribing for children with acute otitis media in the United States, 1998–2004 Figure 6
Trends in Broad-Spectrum Agents prescribing for children with acute otitis media in the United States, 1998–
2004. Based on 6878 visits in the National Ambulatory Medical Care Survey and National Hospital Ambulatory Care Survey. 
Broad-spectrum antibiotics: amoxicillin/clavulanate, macrolides, cephalosporins and quinolones.
Broad-Spectrum Agents 
BMC Pediatrics 2009, 9:41 http://www.biomedcentral.com/1471-2431/9/41
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insurance (compared to private insurance), hospital out-
patient department setting, emergency department set-
ting, and West region (compared to South and Midwest
regions), were each associated with lower rates of broad-
spectrum prescribing. The other two clinical factors, aside
from ear pain, associated with more severe infections –
age and fever- were not independent predictors of broad-
spectrum antibiotic prescribing.
Population Visit Rates
This sample represents an estimated 90 million (95% con-
fidence interval [CI], 83 million-97 million) visits in the
US by children aged 12 years and younger with AOM to
pediatricians, other primary care physicians and clinics,
and emergency departments between 1998 and 2004.
Annual visits for AOM averaged 12.8 million visits per
year, ranging from 15.2 million visits in 1998 to 9.3 mil-
lion visits in 2004. There was a significant change in the
proportion of all visits for children 12 years and younger
diagnosed with AOM over time, decreasing from 10.3% of
visits in 1998 to 6.8% in 2004 (P < .001 for trend).
Discussion
Although amoxicillin remained the recommended antibi-
otic for AOM and PCV had become widely implemented
during the study period, we found that among children
receiving antibiotics, broad-spectrum prescribing steadily
increased from 34% of visits in 1998 to 45% of visits in
2004, a 32% increase over the 7 year interval. An 88%
increase in amoxicillin/clavulanate prescribing and a 67%
increase in macrolide prescribing were largely responsible
for the progressive trend in broad-spectrum usage. So
although fewer children were being diagnosed with AOM,
those that presented for care and received an antibiotic
Table 2: Predictors of broad-spectrum* antibiotic choice among pediatric visits with an antibiotic prescription in United States 
physician's offices, hospital outpatient departments, and emergency departments, 1998–2004
Characteristic Proportion of Visits (%)
(N = 6878)
Visits with a Broad-Spectrum Antibiotic 
Prescription (%)†
Adjusted OR (95% CI) of Broad-Spectrum 
Antibiotic Prescription
Calendar year, per 1 y 100 -- 1.07 (1.05 – 1.10)
Sex
Female 47 46 1.00
Male 53 54 1.02 (0.92 – 1.12)
Age
< 2 years 49 48 1.00
≥ 2 years 51 52 1.05 (0.94 – 1.18)
Race
White 73 78 1.00
Non-White 27 22 0.65 (0.58 – 0.73)
Insurance
Private 43 47 1.00
Medicaid/Medicare 43 41 0.85 (0.76 – 0.95)
Self-pay & Other 14 12 0.76 (0.65 – 0.89)
Physician Specialty‡
Pediatrics 60 59 1.00
Family Practice 37 37 1.07 (0.91 – 1.24)
Otolaryngology 3 4 1.47 (0.96 – 2.25)
Setting
Physician Office 17 22 1.00
Hospital Clinic 29 29 0.77 (0.66 – 0.90)
Emergency Department 54 49 0.61 (0.53 – 0.71)
Region
West 20 16 1.00
South 26 41 2.27 (1.97 – 2.62)
Midwest 33 25 1.38 (1.19 – 1.60)
Northeast 21 18 1.15 (0.98 – 1.35)
Fever
No 62 63 1.00
Yes 38 37 0.96 (0.86 – 1.07)
Ear Pain
No 68 70 1.00
Yes 32 30 0.83 (0.73 – 0.94)
Abbreviations: CI, confidence interval; OR, odds ratio.
*Broad-spectrum antibiotics: amoxicillin/clavulanate, macrolides, cephalosporins and quinolones.
†As a percentage of the total number of patients prescribed an antibiotic.
‡Physician office and hospital outpatient department settings only (N = 3168).BMC Pediatrics 2009, 9:41 http://www.biomedcentral.com/1471-2431/9/41
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prescription had a high likelihood of receiving a broad-
spectrum agent by 2004.
Other studies have looked at the types of antibiotics pre-
scribed for AOM. Broad-spectrum antimicrobials were
used to treat 28% of uncomplicated new AOM infections
in a sample of visits to community pediatricians in 1999–
2000 [22]. More recently, it was found that for children
with AOM less than 2 years of age, 66% received penicil-
lins, 21% cephalosporins, and 11% macrolides including
erythromycin [4]. Amoxicillin/clavulanate prescriptions
were not reported separately. Curiously, in that study,
antibiotics were prescribed in only 58% of visits related to
AOM. Nonetheless, it is difficult to make comparisons
between these results and our analysis which is derived
from a nationally representative sample of visits over a 7
year period. The increased prescribing of macrolides is
consistent with another study [23] and is noteworthy
because of increased streptococcus pneumoniae resistance
to macrolides [24].
We had hypothesized that implementation of PCV after
2000 might have provided physicians with reassurance in
the continued effectiveness of amoxicillin for AOM and
thus lessened their tendency to prescribe broad-spectrum
agents. PCV contains polysaccharides for the five sero-
types of Streptococcus pneumoniae that account for most
of the antibiotic resistance among pneumococci including
high-level resistance to penicillin, macrolide resistance,
and multidrug resistance [25]. Since its introduction,
implementation of PCV has become widespread; coverage
(≥ 3 doses) has increased from 41% of children aged 19 –
35 months in 2002 to 73% in 2004 [26]. Postlicensure
studies have shown a decline in the prevalence of sero-
types with resistance to penicillin [27-30], a reduction in
treatment failures, and a reduction in frequent episodes
and tube procedures [31]. Other studies have suggested
that standard dose, rather than high dose, amoxicillin
may once again be sufficient as first-line therapy in chil-
dren who have received ≥ 3 doses of PCV [32,33]. And in
France, a country with a high prevalence of antibiotic-
resistant pneumococci, implementation of PCV, com-
bined with a reduction in antibiotic use, decreased the car-
riage of penicillin nonsusceptible pneumococci in
children with AOM [34]. One randomized trial, however,
found no reduction in recurrent AOM episodes in the vac-
cine group [35] and a Cochrane review estimated that
AOM episodes would only decrease by 6% to 7% [8].
From our results it does not appear that PCV has affected
prescribing choices. Children less than 2 years of age, for
instance, the group most likely to have been administered
the complete schedule of PCV doses during the study
period, were just as likely as older children to have
received broad-spectrum antibiotics. What may be partic-
ularly concerning about these prescribing trends, in fact, is
their concurrence with PCV implementation. One author
has posed that resistant isolates of Streptococcus pneumo-
niae may reflect an adaptive response of nonvaccine sero-
types to the widespread use of broad-spectrum antibiotics
[36]. This may represent the type of adaptive response that
has contributed to the emergence of multiresistant sero-
types [36]. So, rather than providing reassurance to clini-
cians to continue treating AOM with amoxicillin, PCV, in
combination with broad-spectrum prescribing, may actu-
ally be a contributor to antibiotic resistance. Consistent
with a Swedish study which showed that more children
with AOM are probably being treated at home without
antibiotics [37], we also found that visits for children with
AOM have decreased in recent years. In the US this trend
has been attributed to the national PCV program [4,7].
We also noted that as broad-spectrum antibiotic prescrib-
ing increased, amoxicillin prescribing remain stable,
despite the operant guideline for this time period recom-
mending high dose amoxicillin as first-line therapy for
most children [11]. Of note, the study period ended
before the most recent guidelines on AOM [9], recom-
mending amoxicillin/clavulanate as the initial choice for
children with severe infection, would have had a signifi-
cant impact on amoxicillin prescribing. Encouragingly, we
found a significant decrease in the proportion of patients
receiving narrow-spectrum antibiotics other than amoxi-
cillin from 1998 to 2004. These antimicrobials have been
shown to be less effective options for AOM and are no
longer recommended therapy in the United States
[38,39].
We found that broad-spectrum prescribing was less likely
in those children with ear pain and was not associated
with age or fever; factors characteristic of more severe
infections that might have justified broader coverage
[40,41]. Instead, significant associations were for the non-
clinical factors of race, insurance status, geographical loca-
tion, and ambulatory setting. Over-prescribing of
antibiotics to pediatric white patients has been reported in
another study [42]. High antibiotic prescribing rates have
been found in the South in other studies [43,44]. And
lower rates of nonrecommended (broad-spectrum) anti-
biotics for children with sore throats seen in emergency
departments have been reported as well [42]. In contrast,
general practitioners in the Netherlands were more likely
to overprescribe antibiotics, according to Dutch guide-
lines, to younger children who were more severely ill [45].
Unfortunately, due to limitations in the data, we were
unable to explore associations with other risk factors
linked to the presence of bacterial species likely to be
resistant to amoxicillin. These include attendance at child
care and recent prescription (less than 30 days) of an anti-
biotic [46,47]. However, there is no reason to believe that
these factors would have changed significantly over the 7
year period.BMC Pediatrics 2009, 9:41 http://www.biomedcentral.com/1471-2431/9/41
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There were some aspects of the data that may limit the
conclusions that can be drawn from our results. First, the
NAMCS and NHAMCS survey format does not allow for
direct linkage between diagnosis and medication. Even
though we attempted to use a rigorous method for linking
the antibiotic prescribed during a visit to an AOM diagno-
sis, it is possible that the antibiotics were actually pre-
scribed for a different condition than was addressed in the
visit. Second, as mentioned previously, multiple visits by
the same individual are not accounted for because indi-
vidual identifiers are not coded in NAMCS and NHAMCS.
Lastly, we were unable to determine if high dose amoxicil-
lin (80 to 90 mg/kg/day) was prescribed to children who
received an amoxicillin prescription. High dose amoxicil-
lin was recommended as first line treatment for AOM by
a CDC consensus panel in 1999 due to concerns of drug-
resistant Streptococcus pneumoniae [11]. It is possible
that the rate of prescribing of high dose amoxicillin, in
keeping with these guidelines, increased despite the over-
all stable trend in amoxicillin prescribing.
The CDC has championed national efforts to address anti-
biotic overuse through education of healthcare providers
and the public [48]. And although overall pediatric anti-
biotic prescribing rates [5] and visits for AOM have
decreased [4,7], it is concerning that prescribing for AOM,
now known to be coupled with a high likelihood of a
broad-spectrum antibiotic prescription, has not [6]. Per-
haps the best means of avoiding unnecessary broad-spec-
trum antibiotics for AOM is to limit those children
receiving any antibiotic prescription. In this regard, we
support the national AOM practice guidelines that allow
for the option of observation as the first-line treatment of
uncomplicated AOM in children with mild disease [9].
These guidelines have been further supported by recent,
randomized, controlled trials in multiple settings as well
as several older metaanalyses [49-53]. Adherence to the
guidelines would not only directly decrease antibiotic pre-
scriptions for broad-spectrum and other agents, but per-
haps, also indirectly, as more parents came to learn that a
doctor's visit is not always necessary when their child's
symptoms are mild.
Conclusion
In conclusion, the prescribing of broad-spectrum antibi-
otics for AOM has increased dramatically from 1998 to
2004 and the trend occurred in the midst of the imple-
mentation of a national immunization program effective
in decreasing the severity and incidence of this common
pediatric infection. Physicians have increased their pre-
scribing of broad-spectrum antibiotics for AOM without
correlation to clinical factors such as age or severity of ill-
ness. If primary care physicians decide antibiotics are
needed for AOM, prescribing amoxicillin as initial therapy
is recommended for most children, especially with the
reassurance of its effectiveness provided by PCV.
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